Principal Investigator
PhD. Hanna Allerkamp
Medical University of Graz
GRIP: GLP-1 Receptor Agonists In Preeclampsia Therapy
Preeclampsia is a dangerous pregnancy complication affecting millions of women worldwide. It causes high blood pressure and organ damage, often leading to premature delivery—the only current "cure". Beyond pregnancy, preeclampsia increases the risk of lifelong cardiovascular and metabolic diseases for both mothers and their children. Despite decades of research, effective treatments remain out of reach.
GRIP explores a novel approach to preeclampsia treatment using glucagon-like peptide-1 (GLP-1) receptor agonists, like Ozempic. These drugs, already revolutionizing diabetes and obesity care, show promise for improving vascular health, reducing inflammation, and balancing lipid metabolism—key factors disrupted in preeclampsia. We aim to test whether GLP-1 receptor agonists can restore placental and vascular function in preeclampsia and are safe in pregnancy.
To achieve this, in a collaboration between MedUni and TU Graz, we will combine clinical insights with advanced technology. In a pregnancy cohort (PregWin), we will study GLP-1 levels and metabolic changes across pregnancy. To test drug safety and efficacy, we will develop a cutting-edge 3D "mini-placenta" model. Finally, to examine the effects on crosstalk between placenta, adipose tissue, and maternal blood vessels, we will use tissue samples donated during C-sections in pregnancy specific ex vivo systems. GRIP seeks to pave the way for a safe, effective treatment for preeclampsia. Beyond this, it will build the foundation for a novel pre-clinical pipeline to test drugs for treating pregnancy complications in the future.
Project funding
Funding EUR 499.221,-
